ClassID:

92618

C07C219/22 - CPC Classification

Classification description:

Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings

Recent Application in this class:
#1
20260022091
2026-01-22

POLYMORPHIC FORMS OF (R)-OXYBUTYNIN HYDROCHLORIDE

#2
20260001838
2026-01-01

NANOMATERIALS

#3
20250230126
2025-07-17

INTERMEDIATE OF POLYAMINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF

#4
20230286900
2023-09-14

POLYMORPHIC FORMS OF (R)-OXYBUTYNIN HYDROCHLORIDE

#5
20230234944
2023-07-27

NOVEL COMPOUND USEFUL AS TOLL-LIKE RECEPTOR 7 ACTIVATION INHIBITOR

#6
20220153684
2022-05-19

PROCESS FOR PREPARATION OF FINGOLIMOD HYDROCHLORIDE

#7
20210246344
2021-08-12

Biological buffers with wide buffering ranges

#8
20210230112
2021-07-29

NANOMATERIALS

#9
20210147756
2021-05-20

Biological buffers with wide buffering ranges

#10
20200071582
2020-03-05

Biological buffers with wide buffering ranges

#11
20180296677
2018-10-18

Lipids and lipid compositions for the delivery of active agents

#12
20170313920
2017-11-02

Biological Buffers with Wide Buffering Ranges

#13
20170260435
2017-09-14

Biological Buffers with Wide Buffering Ranges

#14
20160052868
2016-02-25

Biological buffers with wide buffering ranges

#15
20150175526
2015-06-25

Reference markers for fesoterodine fumarate

#16
20140374284
2014-12-25

NOVEL REFERENCE MARKERS FOR FESOTERODINE FUMARATE

#17
20140323530
2014-10-30

Amine derivative compounds for treating ophthalmic diseases and disorders

#18
20140303232
2014-10-09

Lipids and lipid compositions for the delivery of active agents

#19
20130059864
2013-03-07

Inhibiting neurotransmitter reuptake

#20
20120220784
2012-08-30

Process for reduction of alpha-acyloxy sulfide derivatives

#21
20120041039
2012-02-16

Amine derivative compounds for treating ophthalmic diseases and disorders

#22
20120041038
2012-02-16

Amine derivative compounds for treating ophthalmic diseases and disorders

#23
20110218177
2011-09-08

Prodrugs of oxazolidinone CETP inhibitors

#24
20110144188
2011-06-16

SALTS OF TRIMEBUTINE AND N-DESMETHYL TRIMEBUTINE

#25
20100280127
2010-11-04

Inhibiting neurotransmitter reuptake

#26
20100249422
2010-09-30

Acylation reaction of hydroxyl group

#27
20100204516
2010-08-12

Process for the preparation of optically pure R (−) salbutamol and its pharmaceutically acceptable salts

#28
20100076068
2010-03-25

Aminoalcohol Derivatives and Their Therapeutic Use

#29
20100056575
2010-03-04

Anesthetic Compounds

#30
20090326271
2009-12-31

Preparation of 3-[(1,2)-3-(dimethylamino)-1ethyl-2-methylpropyl]phenol

#31
20090281149
2009-11-12

Amine derivative compounds for treating ophthalmic diseases and disorders

#32
20090197924
2009-08-06

2-amino-2-phenyl-alkanol derivatives, their preparation and pharmaceutical compositions containing them

#33
20090170941
2009-07-02

Pharmaceutical compounds

#34
20080287407
2008-11-20

Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use

#35
20070275905
2007-11-29

Salts of trimebutine and N-desmethyl trimebutine

#36
20070197499
2007-08-23

Pharmaceutical compounds

#37
20070043104
2007-02-22

UII-modulating compounds and their use

#38
20060030605
2006-02-09

Nitroderivatives of cardiovascular agents

#39
20050203115
2005-09-15

Narcotic-NSAID ion pairs

#40
20050113580
2005-05-26

Compounds and methods